Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?
10:26am, Friday, 05'th Dec 2025
CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.
CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating
02:56pm, Friday, 14'th Nov 2025
CorMedix delivered strong Q3 results, with DefenCath outperforming expectations and near-term earnings power underestimated in prior analysis. CRMD raised FY25 guidance, but long-term risks remain due
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 12'th Nov 2025
Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of
CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations
11:49am, Wednesday, 12'th Nov 2025
CorMedix Inc. (NASDAQ:CRMD) reported third-quarter earnings of $1.26 per share on Wednesday, beating the consensus of 63 cents.
CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript
11:11am, Wednesday, 12'th Nov 2025
CorMedix Inc. ( CRMD ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Joseph Todisco - CEO & Director Elizabeth Masson-Hurlburt - Executive VP, Chief Operating Officer & Chie
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
07:30am, Wednesday, 12'th Nov 2025
‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue
Wall Street Analysts Predict an 80.58% Upside in CorMedix (CRMD): Here's What You Should Know
10:56am, Monday, 10'th Nov 2025
The mean of analysts' price targets for CorMedix (CRMD) points to an 80.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
Bet on 5 Top-Ranked Stocks With Rising P/E
10:16am, Wednesday, 05'th Nov 2025
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include The Chef's Warehouse, Life Time Group Holdings, The Honest Company, CorMedix and Boston Scientifi
All You Need to Know About CorMedix (CRMD) Rating Upgrade to Strong Buy
01:01pm, Tuesday, 04'th Nov 2025
CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for November 4th
08:26am, Tuesday, 04'th Nov 2025
CRMD, GWRE, TNET, UHS and ISBA have been added to the Zacks Rank #1 (Strong Buy) List on Nov. 4, 2025.
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
08:30am, Friday, 31'st Oct 2025
BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
03:06pm, Thursday, 30'th Oct 2025
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
4 High-Earnings Yield Value Picks Ahead of Potential Fed Rate Cut
09:56am, Wednesday, 29'th Oct 2025
As the Fed readies for another rate cut, value investors could turn to high-earnings-yield stocks like AUGO, CMC, PARR and CRMD.
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
11:41am, Tuesday, 28'th Oct 2025
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in CorMedix Inc $CRMD
05:44am, Monday, 27'th Oct 2025
VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of CorMedix Inc (NASDAQ: CRMD) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutio
